ALICR Stock Overview
Designs, manufactures, and markets alumina-based ceramic implants in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
I.CERAM SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.45 |
| 52 Week High | €6.70 |
| 52 Week Low | €0.41 |
| Beta | 1.09 |
| 11 Month Change | -4.68% |
| 3 Month Change | -10.40% |
| 1 Year Change | -83.03% |
| 33 Year Change | -97.89% |
| 5 Year Change | -98.74% |
| Change since IPO | -99.66% |
Recent News & Updates
Shareholder Returns
| ALICR | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | -0.3% |
| 1Y | -83.0% | 26.7% | -3.5% |
Return vs Industry: ALICR underperformed the French Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: ALICR underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| ALICR volatility | |
|---|---|
| ALICR Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALICR has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALICR's weekly volatility has decreased from 21% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 19 | Andrew Kerisit | www.iceram.fr |
I.CERAM SA designs, manufactures, and markets alumina-based ceramic implants in France and internationally. It offers implants for various joints of the human body, including skull, spine, hip, tibia, ankle, foot, and thorax, as well as osteosynthesis products. The company was incorporated in 2005 and is headquartered in Limoges, France.
I.CERAM SA Fundamentals Summary
| ALICR fundamental statistics | |
|---|---|
| Market cap | €173.55k |
| Earnings (TTM) | -€1.37m |
| Revenue (TTM) | €805.78k |
0.2x
P/S Ratio-0.1x
P/E RatioIs ALICR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALICR income statement (TTM) | |
|---|---|
| Revenue | €805.78k |
| Cost of Revenue | €1.48m |
| Gross Profit | -€679.20k |
| Other Expenses | €690.78k |
| Earnings | -€1.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.54 |
| Gross Margin | -84.29% |
| Net Profit Margin | -170.02% |
| Debt/Equity Ratio | 476.6% |
How did ALICR perform over the long term?
See historical performance and comparison